Autoimmune pancreatitis
Conditions
Interventions
High-dose hormone group:Receive conventional high-dose prednisone treatment [0.6-0.8] mg/kg/d
Medium dose hormone+immunosuppressant group:Receive moderate doses of prednisone (0.4-0.6) mg/kg/d in combination with immunosuppressants (such as azathioprine or mycophenolate mofetil)
Rituximab group:Receiving treatment with the B-cell clearance therapy drug rituximab
Inebilizumab group:Receiving treatment with the B-cell clearance therapy drug Inebilizumab
Sponsors
Peking Union Medical College Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: When patients meet all of the following conditions, they can choose to enter the study (1) Patients between the ages of 18 and 75, regardless of gender, who meet the diagnostic criteria for type 1 AIP: The diagnostic criteria are based on the Chinese guidelines for the diagnosis and treatment of autoimmune pancreatitis (Shanghai, 2023); (2) Recurrent AIP patients: Refers to patients who experience recurrence after receiving standard treatment (such as glucocorticoids/and immunosuppressants), indicating evidence of disease recurrence during follow-up after achieving remission, including laboratory/imaging abnormalities that suggest the recurrence of affected organ damage.
Exclusion criteria
Exclusion criteria: When a patient has any of the following conditions, they cannot be selected to enter the study: (1) Combining clinical conditions similar to IgG4, such as Sjogren's syndrome, polyangitis granulomatous sarcoidosis, eosinophilic granulomatous polyangitis, etc; (2) Merge malignant tumors; (3) Merge severe and irreversible organ damage; (4) Combination of active infections (defined as infections requiring intravenous antibiotic treatment or hospitalization, including active tuberculosis infections and HBsAg (+) patients who have not received anti HBV treatment); (5) Pregnancy or breastfeeding; (6) The researchers believe that it is not suitable for inclusion in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relapse rate after re-induction; | — |
Secondary
| Measure | Time frame |
|---|---|
| Relapse rate;Incidence of AE; | — |
Countries
China
Contacts
Public ContactAiming Yang
Peking Union Medical College Hospital
Outcome results
None listed